SENS Senseonics Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why SENS matters now
Senseonics Holdings, Inc. (SENS) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.38 with +0.56% on the session and $224.9M in market capitalization; recent performance reads 1-month +21.66% and YTD +22.10%.
The latest financial table shown here is Q1 2026, with revenue of $11.7M, net income of $-32.3M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -26.9%.
The latest indexable market news headline is "Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $11.00; recent insider activity includes Goodnow Timothy T filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.99
P/S
6.92
EV/EBITDA
-3.65
DCF Value
$-23.19
FCF Yield
-26.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.1%
Operating Margin
-213.0%
Net Margin
-214.2%
ROE
-130.0%
ROA
-84.8%
ROIC
-111.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.7M | $-32.3M | $-0.71 |
| Q4 2025 | $14.3M | $-20.8M | $-0.50 |
| FY 2025 | $35.3M | $-69.1M | $-1.66 |
| Q3 2025 | $8.1M | $-19.5M | $-0.43 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$8.00 - $14.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.97
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.